Table 1.
Baseline patient characteristics and 3-year transplant-free survival between discovery and validation cohorts.
| Characteristic | Discovery | Validation |
|---|---|---|
| N = 676 | N = 585 | |
| Age (years) | 63 (±13) | 63 (±12) |
| Diagnosis | ||
| CTD-ILD | 310 (46%) | 240 (41%) |
| fHP | 197 (29%) | 140 (24%) |
| IIP | 169 (25%) | 205 (35%) |
| Sex (female) | 415 (61%) | 320 (55%) |
| Race/Ethnicity | ||
| White | 474 (70%) | 472 (81%) |
| Black | 48 (7.1%) | 79 (14%) |
| Hispanic | 92 (14%) | 5 (0.9%) |
| Other/Unknown | 62 (9.2%) | 29 (5.0%) |
| Smoking history | 255 (38%) | 293 (50%) |
| FVC (% predicted) | 66 (±19) | 67 (±20) |
| DLCO (% predicted) | 46 (±18) | 47 (±18) |
| Prior RTX/CYC exposure | 44 (6.5%) | 8 (1.4%) |
| Prednisone use at blood draw | 260 (38%) | 119 (20%) |
| IS use at blood draw | 156 (24%) | 126 (22%) |
| AF use at blood draw | 20 (3.0%) | 26 (4.4%) |
| 3-year transplant-free survival | 445 (66%) | 421 (72%) |
Data are shown as mean (±SD) and n (%). Abbreviations: AF, antifibrotic; CTD-ILD, connective tissue disease-associated interstitial lung disease; CYC, cyclophosphamide; DLCO, diffusion capacity of the lung for carbon monoxide; fHP, fibrotic hypersensitivity pneumonitis; FVC, forced vital capacity; IIP, idiopathic interstitial pneumonia; IS, immunosuppressant medication (mycophenolate, azathioprine, rituximab, or cyclophosphamide); RTX, rituximab.